Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · View financials
Decision snapshot: SRPT stock price vs WDC: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at WDC's multiple
Needs WDC P/S.
Implied fair value · at SRPT's multiple
Needs SRPT P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SRPT FY 2025 (ended Dec 31, 2025) · WDC FY 2026 (ended Jul 3, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
SAREPTA THERAPEUTICS, INC. · implied price per share
Bear
-$43.23
Base
-$50.86
Bull
-$58.48
WESTERN DIGITAL CORPORATION · implied price per share
Bear
$221.57
Base
$260.67
Bull
$299.77
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.82x
0.24x
Net debt / EBITDA
Leverage against operating earnings
0.01x
0.05x
Cash and equivalents
Liquid reserves on the balance sheet
$939.65M
$1.60B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
SRPT vs AMGN
BIOMARIN PHARMACEUTICAL INC
SRPT vs BMRN
Replimune Group, Inc.
SRPT vs REPL
PTC THERAPEUTICS, INC.
SRPT vs PTCT
Seagate Technology Holdings plc
SRPT vs STX
MICRON TECHNOLOGY INC
SRPT vs MU
COMCAST CORP
SRPT vs CMCSA
NetApp, Inc.
SRPT vs NTAP
Pure Storage, Inc.
SRPT vs PSTG
Dell Technologies Inc.
SRPT vs DELL
$934.46M
$2.10B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe SRPT can convert its 15.6% revenue growth into positive margins and improve its quality profile from a Piotroski F-Score of 2/9, then SRPT could be worth holding for upside optionality; otherwise, the current price looks more like a fair reflection of weak fundamentals than a clear mispricing because WDC-implied valuation is unsupported by SRPT's -31.8% operating margin and -61.6% ROIC.
On a P/S basis, SRPT appears massively undervalued versus WDC, with an implied price of $383.86 versus a current price of $14.96, implying 2465.9% upside. However, WDC multiple is dominated by WDC's far richer valuation profile, so the headline gap should be treated cautiously given SRPT's loss-making economics.
Supporting Metrics
